Clinical

Articles

"Perhaps there is another Nobel Prize waiting to be had if we could reduce the cardiovascular effect of ADT and unlock the answer to the controversy surrounding the comparative safety and impact on cardiovascular health between GnRH agonists and antagonists," writes Michael S. Cookson, MD, MMHC.

Prostate cancer and CV risk: The heart of the matter

In this interview, Ardeshir (Art) Rastinehad, DO, discusses the current state of focal therapy in prostate cancer, the role of fusion biopsy in pushing the treatment forward, and what institutions looking to implement focal therapy should know. 

Interest grows for focal therapy in treating prostate cancer

"What will probably be surprising to the reader is that patients managed in markets with higher average prices for prostatectomy were not more likely to undergo treatment," says Lillian Y. Lai, MD.

Study finds commercial prices for prostatectomies are not associated with treatment patterns

Videos

“We're increasingly seeing the addition of molecular and genetic tests to guide us in terms of the cancer treatment that we provide our patients,” says Scarlett Gomez, MD, PhD.

Dr. Scarlett Gomez discusses prostate genomic testing in a world of precision medicine

Following a high intensity interval training exercise regimen was associated with decreased PSA levels in men undergoing active surveillance for prostate cancer.

High-intensity exercise regimen may boost active surveillance outcomes in prostate cancer

The results also showed a trend toward improved overall survival with the combination of the PARP inhibitor and novel hormonal agent; however, the data remain immature.

Olaparib plus abiraterone significantly delays progression in frontline mCRPC

Paige Prostate AI-based software provides pathologists with a supplementary assessment of prostate biopsy images that identifies the area with the highest likelihood of harboring cancer.

FDA authorizes AI-based software for prostate cancer detection

Podcasts

“We need to do a better job sampling the prostate,” says Matthew J. Allaway, MD.

Dr. Allaway on the increased efficiency of transperineal biopsies

The guideline update is supported by findings from the pivotal RTOG 96-01  trial. 

NCCN recommends Decipher genomic test to guide post-RP treatment in high-risk patients 

Abaza is a urologist with Central Ohio Urology Group, Columbus.

Setting expectations and minimizing ports and drains are among steps to take.

Prostate Cancer